Skip to main
TXG
TXG logo

10X Genomics (TXG) Stock Forecast & Price Target

10X Genomics (TXG) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 25%
Hold 42%
Sell 0%
Strong Sell 8%

Bulls say

10x Genomics Inc demonstrates a robust market position, evidenced by significant increases in Chromium reaction volumes, which indicate sustained demand despite potential pricing pressures. The company’s consumables revenue is projected to grow significantly, with estimates suggesting 5-19 times growth across various platforms by 2027, outpacing instrument revenue growth. This positive trend in consumables underscores the effectiveness of 10x Genomics's integrated solutions and reflects a favorable outlook for the company's financial performance moving forward.

Bears say

10x Genomics, Inc. has experienced significant challenges, including a contraction in 2024 characterized by double-digit pricing pressure and flat to modestly lower sales volumes, with growth not projected to recover until 2027. The company recently reported weaker than anticipated quarterly results, with an earnings per share (EPS) miss and a disappointing full-year revenue outlook, further contributing to investor concerns. Additionally, despite some expansion in its market segments since 2021, the growth has fallen short of analyst expectations, resulting in a stock price decline of over 90% from its peak.

10X Genomics (TXG) has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 25% recommend Buy, 42% suggest Holding, 0% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 10X Genomics (TXG) Forecast

Analysts have given 10X Genomics (TXG) a Buy based on their latest research and market trends.

According to 12 analysts, 10X Genomics (TXG) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.96, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.96, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

10X Genomics (TXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.